CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

ANDA 084264

Name: Cyanocobalamin, 1000 mcg

Sponsor: West-ward, Inc.

Approval Date: December 10, 1974

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA 084264

CONTENTS

Reviews / Information Included in this Review

Approval Letter	**X**
Tentative Approval Letter	
Labeling	**X**
Labeling Review(s)	**X**
Medical Review(s)	
Chemistry Review(s)	**X**
Bioequivalence Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Other Review(s)	
Administrative & Correspondence Documents	**X**

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA 084264

APPROVAL LETTER

NDA 84-264

AF 31-015

DEC 10 1974

Weat-ward, Inc.
Attention: Mr. Edward Green
745 Eagle Avenue
Bronx, NY 10456

Gentlemen:

Reference is made to your abbreviated new drug application submitted pursuant to Section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cyanocobalamin Tablets, 1,000 mcg.

We acknowledge receipt of your communications (1) dated August 9, 1974, enclosing final printed container labels and (2) dated October 16, 1974, enclosing final printed package inserts.

We have completed the review of this abbreviated new drug application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved.

Any significant change in the conditions outlined in this abbreviated new drug application, requires an approved supplemental application before the change may be made, except for changes made in conformance with other provisions of Section 314.8 of the new drug regulations.

This Administration should be advised of any change in the marketing status of this drug.

The requirement for adequate data to assure the biologic availability is being deferred at the present time. However, our action in approving this application is based upon an understanding that if this requirement is reinstated you will perform the appropriate procedures.

The enclosures summarize the conditions relating to the approval of this application.

Sincerely yours,

Marvin Seife 12/10/74

Marvin Seife, M.D.
Director
Division of Generic Drug Monographs
Office of Drug Monographs
Bureau of Drugs

cc:
NYK-DO
HFD-107
HFD-8
HFD-106
HFD-12
JRCarr/JLMeyer/JMRoss/11-27-74
R/D init. by MSeife/JMeyer/11-27-74

J.M. Ross 12-9-74

Enclosures:
Conditions of Approval of a New Drug Application
Records and Reports Requirement

JMeyer 12/9/74

Final typing/kim/12-4-74

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA 084264

LABELING

CYANOCOBALAMIN (VITAMIN B12)
ORAL

DESCRIPTION: Cyanocobalamin appears as dark red crystals. It is very hygroscopic in the anhydrous form, and sparingly soluble in water (1:80). The vitamin B_{12} coenzymes are very unstable in light.

The chemical name is 5,6-dimethyl-benzimidazolyl-cyanocobalamin. The empirical formula is: $C_{63}H_{88}CoN_{14}O_{14}P$. The cobalt content is 4.34%.

ACTIONS: Vitamin B_{12} is essential to growth, cell reproduction, hematopoiesis, nucleoprotein and myelin synthesis.

APPROVED DEC 10 1974

INDICATIONS FOR USE: Pernicious anemia with mild or no neurologic signs in the rare patient having idiosyncrasy or sensitivity to parenteral administration or when parenteral therapy is refused.

As adjunctive treatment in megaloblastic anemia associated with sprue.

WARNINGS: Parenteral administration of Vitamin B_{12} is the preferred treatment for pernicious anemia particularly for the initial treatment. Some patients with pernicious anemia may not respond to oral vitamin B_{12}.

Protect from light.

Vitamin B_{12} deficiency allowed to progress over 3 months may produce permanent degenerative lesions of the spinal cord, as observed when folic acid therapy is used as the only hematopoietic agent.

Lack of therapeutic response may be due to infection, uremia, chloramphenicol and misdiagnosis.

PRECAUTIONS: Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B_{12} diagnostic blood assays.

Colchicine, para-aminosalicylic acid and heavy alcohol intake longer than 2 weeks may produce malabsorption of vitamin B_{12}. A dietary deficiency of only vitamin B_{12} is rare. Multiple vitamin deficiency is expected in any dietary deficiency.

ADVERSE REACTIONS: Mild transient diarrhea, polycythemia vera, itching, transitory exanthema, feeling of swelling of entire body.

DOSAGE AND ADMINISTRATION:

A. General Rules:

In patients with Addisonian Pernicious Anemia treatment will be required for the remainder of the patient's life. Reticulocyte plasma count, vitamin B_{12} and folic acid must be obtained prior to treatment and between the fifth and seventh day of therapy.

B. Treatment of Vitamin B_{12} Deficiency:

The usual or recommended dose is 1000 mcg. daily. Folic acid should be coadministered early in the treatment unless adequate.

HOW SUPPLIED: Compressed Tablets (Soluble) each containing 1000 mcg. Cyanocobalamin U.S.P. in bottles of 100

CAUTION: Federal law prohibits dispensing without a prescription.

West-ward, Inc.
JUNE 1974

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA 084264

LABELING REVIEWS

REVIEW OF RESUBMISSION

DATE COMPLETED: 9-18-74

ANDA #: 84-264

CO. NAME: West-Ward, Inc.
745 Eagle Ave.
Bronx, NY 10456

NAME OF DRUG: Cyanocobalamin Tablets, 1000 ~~mg~~ mcg.

DATE OF SUBMISSION: 8-9-74

TYPE OF SUBMISSION: Resubmission;

CLINICAL EVALUATION:

1. Review of Studies: None submitted

2. Review of Labeling:

Container label for containers of 100 tablet only - Satisfactory

CONCLUSION: The container labels in this submission are acceptable.

RECOMMENDATION: The company is to be so notified.

J.R. Carr

J.R. Carr, D.D.S.

cc:
Dup
HFD-107
JRCarr, D.D.S./kim/9-18-74

REVIEW OF RESUBMISSION

DATE COMPLETED: 8-12-74

ANDA #: 84-264

CO. NAME: West-ward, Inc.
745 Eagle Ave.
Bronx, NY 10456

NAME OF DRUG: Cyanocobalamin Tablets, 1000 mcg.

DATE OF SUBMISSION: 6-17-74

TYPE OF SUBMISSION: Resubmission

CLINICAL EVALUATION:

1. Review of Studies: None submitted

2. Review of Labeling:

a. Container labels: None submitted

b. Package insert: (draft copy) Conform to labeling guidelines and is satisfactory. (The sentence under Dosage and Administration that the company refers to makes as much sense as most of the vitamin labeling).

CONCLUSION: The draft copy of the package insert is acceptable. Have the firm send in FPL identical in content to the draft copy.

RECOMMENDATION: The company is to be so notified.

J.R. Carr

J.R. Carr, D.D.S.

cc:
Dup
HFD-107
JRCarr, D.D.S./kim/8-12-74

REVIEW OF ANDA

DATE COMPLETED: 4-25-74

ANDA #: 84-264

F.R. DATE: 2-15-73

CO. NAME: West-ward, Inc.
745 Eagle Ave
Bronx, NY 10456

NAME OF DRUG: Cyanocobalamin Tablets, 1000 mcg.

DATE OF SUBMISSION: 4-11-74

TYPE OF SUBMISSION: ANDA

CLINICAL EVALUATION:

1. Review of Studies: None submitted

2. Review of Labeling:

   a) Container labels: Draft copy for containers of 100 tablets - Satisfactory

   b) Package insert: Needs to be revised in accord with labeling guidelines.

CONCLUSION:
1. The draft copy of the container label is satisfactory.
2. The draft copy of the package insert needs revision as noted above.

RECOMMENDATIONS: The company is to be so notified and sent a copy of the labeling guidelines.

JR Carr

J.R. Carr, D.D.S.

cc:
Dup
HFD-107
JRCarr/wlb/4-29-74

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA 084264

CHEMISTRY REVIEWS

CHEMIST'S REVIEW FOR ABBREVIATED NEW DRUG APPLICATION OR SUPPLEMENT

Statement Date: 2-15-73

AF Number: 84-264 31-015

Original
Amendment x
Supplement
Resubmission
Correspondance
Report
Other

Name and Address of Applicant (City and State)

West-ward, Inc.
745 Eagle Avenue
Bronx, NY 10456

Purpose of Amendment/Supplement

submission of final printed labels

Date(s) of Submission(s)

7-9-74
10-16-74

Pharmacological Category	Name Of Drug	How Dispensed
Vitamin	Cyanocobalamin	Rx [x] OTC [ ]
Dosage Form(s)	Potency	
tablet	1000 mcg.	
Environmental Impact Analysis Report	Samples	Related IND/NDA/MF(s)
submitted		

Labeling

Container label: Satisfactory(JRCarr)
Package insert: " "

Biologic Availability

deferred according to Dr. M. Seife

Establishment Inspection

West-ward, Inc. in compliance 7-31-73
(b) (4) in compliance 5-1-74

Components, Composition, Manufacturing and Controls

active ingredient, excipients, finished dosage form are tested according to USP specs.

Remarks

Conclusion: Approved

Reviewer: J.M.Ross J.M. Ross 12-9-74 Date:

CHEMIST'S REVIEW FOR ABBREVIATED NEW DRUG APPLICATION OR SUPPLEMENT

Federal Register Statement Date: 2-15-73

NDA Number: 84-264

AF Number: 31-015

Original:
Amendment: X
Supplement:
Resubmission:
Correspondance:
Report:
Other:

Name and Address of Applicant (City and State)

West-ward, Inc.
745 Eagle Avenue
Bronx, NY 10456

Purpose of Amendment/Supplement

revise package insert submitted

Date(s) of Submission(s)

6-17-74

Pharmacological Category	Name Of Drug	
Vitamin	Cyanocobalamin	
Dosage Form(s)	Potency	How Dispensed
tablet	1000 mcg	Rx [X] OTC [ ]
Environmental Impact Analysis Report	Samples	Related IND/NDA/MF(s)
submitted		

Labeling

Container label: Satisfactory (Chem. Rev. of 6-1-74- JRCarr)
Package insert : Satisfactory (JRCarr)

Biologic Availability

Deferred (M Seife)

Establishment Inspection

West-ward, Inc. in compliance 7-31-73
(b) (4) in compliance 5-1-74

Components, Composition, Manufacturing and Controls

active ingredient, excipients, & finished dosage form are tested according to USP specs

Remarks

Requested: FPL of container label & package inert

Conclusion: Approvable

Reviewer: J.M.Ross J M Ross 8-29-74

Date:

CHEMIST'S REVIEW FOR ABBREVIATED NEW DRUG APPLICATION OR SUPPLEMENT

Federal Register Statement Date 2-15-73

NDA Number 31-015

AF Number

Name and Address of Applicant (City and State)

West-Ward, Inc.
745 Eagel Avenue
Bronx, NY 10456

Original
Amendment
Supplement
Resubmission
Correspondance
Report
Other

Date(s) of Submission(s)

Purpose of Amendment/Supplement

New Application

Pharmacological Category	Name Of Drug	
Vitamin	Cyanocobalamin	
Dosage Form(s)	Potency	How Dispensed
tablet	1000 mcg	Rx [x] OTC [ ]
Environmental Impact Analysis Report	Samples	Related IND/NDA/MF(s)
submitted		

Labeling

Container label: Satisfactory(JRCarr)
Package insert: Revise according to m.o. report (JRCarr)

Biologic Availability

Deferred

Establishment Inspection

WestWard, Inc. - in compliance 7-31-73

(b) (4) - in compliance 5-1-74

Components, Composition, Manufacturing and Controls

Satisfactory according to USP specifications

Remarks

Requested:
1. FPL of container labels
2. Package insert: revise according to labeling guidelines

Conclusion rev w/f

Reviewer: J.M.Ross J. M. Ross 6-10-74

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

ANDA 084264

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS

ORIG

NOTICE OF APPROVAL
NEW DRUG APPLICATION OR SUPPLEMENT

NDA NUMBER: 84-264

DATE APPROVAL LETTER ISSUED: DEC 10 1974

TO: Press Relations Staff *(CE-300)*

FROM: [X] Bureau of ~~xxxxxx~~ Drugs
[ ] Bureau of Veterinary Medicine

ATTENTION

Forward original of this form for publication only after approval letter has been issued and the date of approval has been entered above.

Original

TYPE OF APPLICATION: [ ] ORIGINAL NDA [ ] ABBREVIATED [X] ORIGINAL NDA [ ] SUPPLEMENT TO NDA

CATEGORY: [X] HUMAN [ ] VETERINARY

TRADE NAME *(or other designated name)* AND ESTABLISHED OR NONPROPRIETARY NAME *(if any)* OF DRUG

Cyanocobalamin

DOSAGE FORM: tablet

HOW DISPENSED: [X] RX [ ] OTC

ACTIVE INGREDIENT(S) *(as declared on label. List by established or nonproprietary name(s) and include amount(s), if amount is declared on label.)*

Cyanocobalamin 1000 mcg

NAME OF APPLICANT *(Include City and State)*

West-ward, Inc.
745 Eagle Avenue
Bronx, NY 10456

PRINCIPAL INDICATION OR PHARMACOLOGICAL CATEGORY

Vitamin

COMPLETE FOR VETERINARY ONLY

ANIMAL SPECIES FOR WHICH APPROVED

COMPLETE FOR SUPPLEMENT ONLY

CHANGE APPROVED TO PROVIDE FOR

FORM PREPARED BY

NAME: J.M.Ross — DATE:

FORM APPROVED BY

NAME: J.L.Meyer — DATE:

FD FORM 1642 (7/69) PREVIOUS EDITION MAY BE USED UNTIL SUPPLY IS EXHAUSTED.

NDA 84-264

AF 31-015

SEP 0 3 1974

West-ward, Inc.
Attention: Mr. Edward Green
745 Eagle Avenue
Bronx, NY 10456

Gentlemen:

Reference is made to your abbreviated new drug application, dated April 11, 1974, submitted pursuant to Section 505(b) of the Federal Food, Drug, and Cosmetic Act, for Cyanocobalamin Tablets, 1000 mcg.

We acknowledge receipt of your communication, dated June 17, 1974, enclosing a revised draft package insert.

We have completed the review of this abbreviated application as submitted with draft labeling. However, before the application may be approved, it will be necessary for you to submit final printed labeling. The labeling should be identical in content to the draft copy.

Please submit twelve copies of the printed labeling.

Sincerely yours,

Marvin Seife, M.D.
Director
Generic Drug Staff
Office of Scientific Evaluation
Bureau of Drugs

cc:
NYK-DO
Dup
HFD-107
HFD-106
HFD-13
HFD-8
JRCarr/JLMeyer/JMRoss/8-27-74
R/D init. JMeyer/8-27-74
Final typing/rt/8-27-74
Approvable

J. M. Ross 8-29-74

JMeyer 8/29/74

NDA 84-264

AF 31-015

JUN 12 1974

West-ward, Inc.
Attention: Mr. Edward Green
745 Eagle Avenue
Bronx, NY 10456

Gentlemen:

Reference is made to your abbreviated new drug application dated April 11, 1974, submitted pursuant to Section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cyanocobalamin Tablets, 1000 mcg.

We have completed our review of this abbreviated application. However, before we are able to reach a final conclusion, the following additional information is necessary:

1. Container labels: Please submit twelve copies of printed labels. The labels should be identical in content to the draft copy.

2. Package Insert: Revise in accordance with enclosed labeling guidelines.

Please submit the above information promptly.

Sincerely yours,

Marvin Seife 6/12/74

Marvin Seife, M.D.
Director
Generic Drug Staff
Office of Scientific Evaluation
Bureau of Drugs

Enclosure: labeling guidelines

cc: JMeyer 6/11/74
NYK-DO
Dup
HFD-107 HFD-106 HFD-13 HFD-8
JRCarr/JLMeyer/JMRoss/6-4-74
R/D init. MSeife/JMeyer/6-6-74
Final typing/rt/6-7-74
rev w/f

JR Carr 6/10/74

JM Ross 6-10-74

NDA 84-264

AF 31-015

APR 2 4 1974

West-Ward, Incorporated
Attention: Mr. Edward Green
745 Eagle Avenue
Bronx, New York 10456

Gentlemen:

We acknowledge the receipt of your abbreviated new drug application submitted pursuant to section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

NAME OF DRUG: Cyanocobalamin Tablets, 1000 mcg.

DATE OF APPLICATION: April 11, 1974

DATE OF RECEIPT: April 12, 1974

We will correspond with you further after we have had the opportunity to review the application.

We would also like to call to your attention the Federal Register of March 15, 1973 (38 F.R. 7001) regulations establishing procedures for preparation of Environmental Impact Statements (Part 6 - Environmental Impact Considerations). Section 6.1(a) of these regulations requires that the applicant include an environmental impact analysis report as part of any new-drug application. Failure to submit an environmental impact analysis report is grounds for refusing to file or to approve an application (21 CFR 130.5(a)(8) or 130.12(a)(7)).

Please identify any communications concerning this application with the NDA number shown above.

Sincerely yours,

Marvin Seife 4/24/74

Marvin Seife, M.D.
Director
Generic Drug Staff
Office of Scientific Evaluation
Bureau of Drugs

cc: NYK-DO
HFD-107 HFD-8
HFD-310
JLMeyer/4/17/74/ep/4/19/74
R/D init. by: MSeife/4/18/74

ACK JLMeyer 4/23/74